1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
JD Health International Inc.

JD Health International Inc.

JDHIY
JD Health International Inc.US flagOther OTC
4.50
USD
-0.15
- -
14.45BMarket Cap
JD Health International Inc.
JDHIY
(Other OTC)

Recent

price

4.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
1.78
2.61
3.47
8.78
9.91
15.04
17.14
18.51
23.22
Revenue per Share
0.06
0.07
-0.31
-7.8
-0.35
0.12
0.69
1.32
1.7
Basic EPS, GAAP
0.01
0.06
0.13
1.66
0.94
1.17
1.45
1.36
3.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
-0.03
-0.44
-8.43
-6.37
-6.24
-5.55
-4.21
-2.52
Book Value per Share
0.21
0.24
-0.15
17.76
12.87
13.68
15.11
16.91
18.38
Tangible Book Value per Share
3,127
3,127
3,127
2,209
3,095
3,107
3,124
3,143
3,163
Basic Weighted Avg Shares
5,553
8,169
10,842
19,383
30,682
46,736
53,530
58,160
73,441
Sales/Revenue/Turnover
4.62
3.76
4
1.81
-4.45
-0.1
1.31
2.54
5.37
Operating Margin (%)
3
6
7
27
63
141
227
215
280
Depreciation Expense
179
215
-972
-17,234
-1,074
380
2,142
4,162
5,375
Net Income, GAAP
30.25
29.82
- -
- -
- -
44.92
20.44
13.34
10.99
Effective Tax Rate (%)
3.22
2.63
-8.96
-88.92
-3.5
0.81
4
7.16
7.32
Profit Margin (%)
654
736
7,079
38,023
37,700
40,091
33,265
42,939
35,607
Working Capital
2
2
6
61
134
129
119
149
429
LT Debt
663
749
-459
39,251
39,855
44,785
49,370
55,241
60,073
Total Equity
- -
30.38
- -
- -
- -
-0.06
1.17
2.43
6.01
Return on Invested Capital (%)
- -
-310.67
- -
- -
- -
-1.97
-11.84
-27.77
-53.17
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.96%
8.75%
Free Cash Flow
- -
31.5%
133.85%
Net Income, GAAP
- -
71.56%
29.16%
Sales/Revenue/Turnover
- -
32.02%
26.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
53,530
2024
- -
- -
- -
- -
58,160
2025
- -
- -
- -
- -
73,441

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.69
2024
- -
- -
- -
- -
1.32
2025
- -
- -
- -
- -
1.7

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
IMAC Holdings, Inc. (IMAC)
NewGenIvf Group Limited (NIVF)
LHC Group, Inc. (LHCG)
Bangkok Chain Hospital Public Company Limited (BCH-R.BK)
Al-Modawat Specialized Medical Co. (9594.SR)
Humana AB (publ) (HUM.ST)
Business
JD Health International Inc. (JDHIY) operates as China's largest online healthcare platform, providing pharmaceutical and healthcare products; internet healthcare services; health management solutions; and intelligent healthcare technologies through an integrated ecosystem. The company offers an extensive range of core products and services, including online and offline retail of medicines, medical devices, nutritional supplements, and pet healthcare items via direct sales, marketplace, and on-demand delivery channels; healthcare services such as telemedicine consultations, online medical insurance payments, home care encompassing wound care, diagnostics, post-operative support, and medical escorts; traditional Chinese medicine wellness, orthopedic treatments, and operations of examination centers and polyclinics; as well as digital solutions like smart monitoring devices, respiratory therapy equipment, senior medical devices, and large language model-enabled internet hospitals. Founded in 2014 and headquartered in Beijing, JD Health primarily serves individual consumers, corporate clients, medical institutions, and pharmaceutical companies across China, with a subsidiary relationship to JD Jiankang Limited. Recent developments include a strategic partnership with Novo Nordisk in 2024 to deliver integrated solutions for obesity, diabetes, and related conditions spanning prevention, diagnosis, treatment, and management; a collaboration with Intco Medical for co-development of customized physiotherapy products under a C2M model; the 2022 acquisition of JD.com's pet health assets to bolster its pet care ecosystem; and sustained R&D investment growth to RMB1.3 billion in 2024, alongside positioning as the first online marketplace for new and specialty drug launches.

Company News

APIChatGPT

  • seekingalpha.com

    JD Health International Inc. (JDHIY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    JD Health International Inc. (JDHIF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    JD Health International Inc. (JDHIF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    JD Health: Becoming Bullish On Tailwinds And Catalysts (Rating Upgrade)

  • seekingalpha.com

    JD Health International Inc. (JDHIF) Q4 2023 Earnings Call Transcript

  • investorplace.com

    Don't Miss the Boom: 3 Pharma Stocks Set to Explode Higher

  • seekingalpha.com

    JD Health International Inc. (JDHIF) Q4 2022 Earnings Call Transcript